<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Kawasaki disease: Complications
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Kawasaki disease: Complications
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Kawasaki disease: Complications
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Robert Sundel, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Marisa Klein-Gitelman, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sheldon L Kaplan, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Philip Seo, MD, MHS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 11, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2507732">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kawasaki disease (KD, also called mucocutaneous lymph node syndrome) is one of the most common vasculitides of childhood [
         <a href="#rid1">
          1
         </a>
         ]. KD also occurs rarely in adults. It is typically a self-limited condition, with fever and manifestations of acute inflammation lasting for an average of 12 days without therapy [
         <a href="#rid2">
          2
         </a>
         ]. However, complications such as coronary artery aneurysms, depressed myocardial contractility and heart failure, myocardial infarction, arrhythmias, and peripheral arterial occlusion may develop and lead to significant morbidity and mortality  (
         <a class="graphic graphic_table graphicRef56475" href="/z/d/graphic/56475.html" rel="external">
          table 1
         </a>
         ). Noncardiac complications may also affect children with KD.
        </p>
        <p>
         The complications of KD are discussed in this topic review, with long-term cardiovascular sequelae of KD reviewed in greater detail separately. The epidemiology, etiology, clinical manifestations, diagnosis, and treatment of KD, refractory KD, and incomplete (atypical) KD are also presented separately. (See
         <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">
          "Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6416.html" rel="external">
          "Kawasaki disease: Epidemiology and etiology"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">
          "Kawasaki disease: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">
          "Kawasaki disease: Initial treatment and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6408.html" rel="external">
          "Refractory Kawasaki disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15689.html" rel="external">
          "Incomplete (atypical) Kawasaki disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2507746">
         <span class="h1">
          SHOCK
         </span>
         <span class="headingEndMark">
          —
         </span>
         KD shock syndrome (KDSS), defined as sustained systolic hypotension (decrease in blood pressure greater than 20 percent from baseline) or clinical signs of poor perfusion, is a potentially life-threatening complication of KD [
         <a href="#rid3">
          3,4
         </a>
         ]. It may be accompanied by multiple organ dysfunction syndrome (MODS), with MODS seen in 8 of 11 patients with KD and shock in one series [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         It is important to distinguish patients with KDSS from those with other causes of severe hypoperfusion since aggressive use of intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG), which is essential for the successful control of KDSS, is not typically used in other types of shock. Features that may help distinguish KDSS from other types of shock (see
         <a class="medical medical_review" href="/z/d/html/6396.html" rel="external">
          "Initial evaluation of shock in children"
         </a>
         ) include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Thrombocytosis
         </strong>
         – Thrombocytosis is a characteristic finding in KDSS, whereas thrombocytopenia is more common in other types of shock (eg, toxic shock syndrome [TSS] and septic shock). However, in one study of 13 children with KDSS, 7 (54 percent) had thrombocytopenia with a mean platelet nadir of 54.3 cells/microL, potentially complicating the distinction between KDSS and other types of shock [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Younger age
         </strong>
         – Patients with KDSS are typically younger than those with TSS (mean age approximately three years versus nine years, respectively) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Echocardiographic abnormalities
         </strong>
         – Coronary artery abnormalities (CAAs), when present, are highly suggestive of KD. Additional echocardiographic abnormalities including valvulitis, mitral regurgitation, and impaired left ventricular systolic function are more prevalent in KDSS than in KD patients who are hemodynamically stable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one case series from a single institution, 13 of 187 consecutive patients with KD (7 percent) presented with KDSS between 2003 and 2007 [
         <a href="#rid3">
          3
         </a>
         ]. All patients with KDSS received fluid resuscitation, and seven also received inotropic agents. Patients with shock syndrome were more likely than KD patients who were hemodynamically stable to have consumptive coagulopathy and cardiac abnormalities. In addition, patients who presented with shock had higher C-reactive protein (CRP) levels than those with uncomplicated KD. Most importantly, children with KDSS were also less responsive to initial
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         therapy and more commonly required additional treatment for their KD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2507753">
         <span class="h1">
          CARDIAC COMPLICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The major complication of KD is coronary artery abnormalities (CAAs), which can include dilation, aneurysm, and/or stenosis  (
         <a class="graphic graphic_table graphicRef113212" href="/z/d/graphic/113212.html" rel="external">
          table 2
         </a>
         ). Patients also can develop depressed ventricular function in the acute phase, valvular regurgitation, and pericardial effusions. Late cardiovascular complications include progressive coronary artery stenosis or occlusion, myocardial infarction, and arrhythmias. These late complications are generally limited to patients who had CAAs in the acute phase. Acute myocardial infarction (AMI) is the main cause of death in KD. The risk of AMI is highest in children with giant CAA aneurysms. (See
         <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">
          "Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2507760">
         <span class="h2">
          Coronary artery abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         CAAs are the most serious complication of KD  (
         <a class="graphic graphic_movie graphicRef65317" href="/z/d/graphic/65317.html" rel="external">
          movie 1
         </a>
         and
         <a class="graphic graphic_movie graphicRef53864" href="/z/d/graphic/53864.html" rel="external">
          movie 2
         </a>
         and
         <a class="graphic graphic_movie graphicRef76878" href="/z/d/graphic/76878.html" rel="external">
          movie 3
         </a>
         ). The frequency of CAAs in KD and the associated mortality have decreased dramatically as a result of intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) therapy [
         <a href="#rid7">
          7
         </a>
         ]. Patients treated with IVIG within the first 10 days of illness have an approximately 75 percent decrease in the risk of developing coronary artery aneurysms and a more than 95 percent decrease in mortality. While CAAs occur in approximately one-quarter of KD patients in the IVIG era, most of these patients have small, reversible coronary artery dilatation, not true aneurysms. (See
         <a class="medical medical_review" href="/z/d/html/6423.html" rel="external">
          "Kawasaki disease: Initial treatment and prognosis", section on 'Intravenous immune globulin'
         </a>
         .)
        </p>
        <p>
         CAAs are classified based upon Z-score (the number of standard deviations below or above the population mean coronary diameter adjusted for sex and body surface area)  (
         <a class="graphic graphic_table graphicRef113212" href="/z/d/graphic/113212.html" rel="external">
          table 2
         </a>
         ). CAAs typically increase over the first four to six weeks after illness onset, and approximately one-half regress to normal lumen diameter over the subsequent two years. The likelihood that an aneurysm will regress to normal lumen diameter (Z-score &lt;2) is most strongly related to its maximum diameter. Giant aneurysms (defined as Z-score &gt;10, typically ≥8 mm internal diameter in children under five years of age) are least likely to regress. They are associated with the highest risk of morbidity and mortality. Up to 50 percent of such aneurysms become obstructed, leading to myocardial infarction, arrhythmias, or sudden death. A far larger percentage of children KD have subtle and often transient coronary artery changes. The acute evaluation, treatment, natural history, and long-term monitoring of coronary artery aneurysms are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">
          "Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"
         </a>
         .)
        </p>
        <p>
         Factors associated with increased risk of CAAs that are most consistently reported in the available studies include the following [
         <a href="#rid8">
          8-10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Late diagnosis and delayed treatment with
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age younger than one year or older than nine years
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Male sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Fever ≥14 days
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum sodium concentration &lt;135 mEq/L
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hematocrit &lt;35 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White blood cell count &gt;12,000/mm
         <sup>
          3
         </sup>
        </p>
        <p>
        </p>
        <p>
         Additional risk factors are discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">
          "Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation", section on 'Risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2507767">
         <span class="h2">
          Ventricular dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence of mild to moderate ventricular dysfunction is commonly seen on echocardiography during the acute phase of KD. Rarely, function is severely depressed. Depressed ventricular function during the acute phase may manifest as an S3 gallop that becomes more prominent with hydration. In rare cases, it may progress to heart failure. Depressed ventricular function may be caused by direct myocardial inflammation (ie, myocarditis) or from indirect negative inotropic effects of the systemic inflammatory response. Treatment with
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         usually restores normal ventricular function rapidly [
         <a href="#rid11">
          11
         </a>
         ]. On the other hand, lymphocytic infiltrates or fibrosis are sometimes noted on endomyocardial biopsy even years after the acute illness, especially in children who do not receive IVIG [
         <a href="#rid12">
          12
         </a>
         ]. In addition, ischemic cardiomyopathy may occur in patients with coronary artery aneurysms after myocardial infarction. (See
         <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">
          "Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation", section on 'Ventricular dysfunction'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1305931109">
         <span class="h1">
          MACROPHAGE ACTIVATION SYNDROME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Macrophage activation syndrome (MAS, also called secondary hemophagocytic lymphohistiocytosis [HLH]) is characterized by activation and proliferation of macrophages and T cells. This may lead to severe complications including disseminated intravascular coagulopathy, cytopenias, and thrombosis. MAS may complicate a variety of infections, rheumatologic conditions, and malignancies. It has been described rarely in children with KD who have persistent and sustained fever after intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) treatment [
         <a href="#rid13">
          13-21
         </a>
         ]. A small number of children with secondary HLH have mutations of perforin or other genes that are more typically associated with congenital HLH [
         <a href="#rid22">
          22
         </a>
         ]. The clinical features of HLH and the diagnosis and treatment of MAS are reviewed in greater detail separately. The primary medications chosen for treatment of MAS are guided by the underlying disease. Thus, IVIG and systemic glucocorticoids are the first choice medications for MAS in children with KD. (See
         <a class="medical medical_review" href="/z/d/html/13512.html" rel="external">
          "Systemic juvenile idiopathic arthritis: Course, prognosis, and complications", section on 'Macrophage activation syndrome'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8384.html" rel="external">
          "Treatment and prognosis of hemophagocytic lymphohistiocytosis"
         </a>
         .)
        </p>
        <p>
         A retrospective review of 719 Chinese patients with KD found that slightly more than 1 percent had MAS [
         <a href="#rid23">
          23
         </a>
         ]. Cases with MAS were characterized by hepatosplenomegaly, cytopenias, hypofibrinogenemia (&lt;1.5 g/L), and hyperferritinemia, findings not usually seen in uncomplicated cases of KD. However, hemophagocytosis was evident in only three cases, and commonly used criteria for the diagnosis of HLH [
         <a href="#rid24">
          24
         </a>
         ] correctly identified only one case of MAS complicating KD. The preliminary MAS diagnostic guidelines (Ravelli criteria) were more accurate in identifying patients with MAS in this setting [
         <a href="#rid25">
          25
         </a>
         ]. Seven of eight patients with MAS were nonresponders to
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         , two developed coronary artery ectasia, and one of the eight died. Thus, early recognition of MAS as a complication of KD is crucial, both in order to optimize treatment for KD and to administer potentially lifesaving therapy for the MAS.
        </p>
        <p class="headingAnchor" id="H2507774">
         <span class="h1">
          NONCORONARY VASCULAR INVOLVEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1151796710">
         <span class="h2">
          Types of arteries involved
         </span>
         <span class="headingEndMark">
          —
         </span>
         KD has a definite but unexplained predilection for coronary arteries, although virtually any vascular bed may be affected. Medium-sized muscular arteries (eg, axillary, iliac, brachial, and mesenteric) are the most commonly involved. While small arteries, veins, and visceral vessels are relatively spared [
         <a href="#rid26">
          26
         </a>
         ], vascular changes may uncommonly occur in peripheral and visceral arteries.
        </p>
        <p class="headingAnchor" id="H625974893">
         <span class="h2">
          Peripheral vascular involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peripheral arterial obstruction can lead to ischemia and gangrene. This complication generally accompanies other manifestations of severe disease, such as giant coronary artery aneurysms and aneurysms in peripheral arteries [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1802339486">
         <span class="h2">
          Visceral vascular involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         KD can affect the vasculature in numerous organ systems other than the heart, but clinically significant vasculitis is unusual. Among the rare extra-cardiac presentations of KD are cases involving the gastrointestinal tract, kidneys, and central nervous system. Other diagnoses, especially systemic vasculitides such as Takayasu arteritis and polyarteritis nodosa, should be considered when the presenting features are atypical. (See
         <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">
          "Kawasaki disease: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2507781">
         <span class="h3">
          Urinary abnormalities and kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the exception of sterile pyuria, urinary abnormalities and kidney disease are uncommonly associated with KD. Among the kidney complications noted in selected cases are acute interstitial nephritis, mild proteinuria, and acute kidney injury (AKI) [
         <a href="#rid28">
          28-30
         </a>
         ]. AKI is a rare complication, and the underlying pathologic processes vary in different patients. Hemolytic uremic syndrome, immune complex-mediated glomerulonephritis, and acute interstitial nephritis, for example, have each been reported in a handful of cases [
         <a href="#rid29">
          29,30
         </a>
         ]. As with all unusual manifestations of KD, other diagnoses must be seriously entertained when organs other than the heart are involved. (See
         <a class="medical medical_review" href="/z/d/html/6126.html" rel="external">
          "Acute kidney injury in children: Clinical features, etiology, evaluation, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6081.html" rel="external">
          "Clinical manifestations and diagnosis of Shiga toxin-producing Escherichia coli (STEC) hemolytic uremic syndrome in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects", section on 'Complications affecting the kidney'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2507788">
         <span class="h3">
          Gastrointestinal abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Children with KD may present with a wide variety of gastrointestinal manifestations. Hydrops of the gallbladder is a common finding during the acute phase of KD. It may persist in untreated cases but generally resolves rapidly after intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG). A case series from Italy reported 10 children with gastrointestinal symptoms that were not immediately recognized as due to KD. There were five patients with gallbladder hydrops and cholestasis, three with paralytic ileus, one with appendicular vasculitis, and one with hemorrhagic duodenitis [
         <a href="#rid31">
          31
         </a>
         ]. Other reports document KD presenting as gastrointestinal obstruction [
         <a href="#rid32">
          32
         </a>
         ] or pseudoobstruction [
         <a href="#rid33">
          33,34
         </a>
         ], intussusception [
         <a href="#rid35">
          35
         </a>
         ], pancreatitis [
         <a href="#rid36">
          36,37
         </a>
         ], and bile duct stenosis [
         <a href="#rid37">
          37
         </a>
         ]. In such atypical cases, consideration must be given to alternative diagnoses, such as macrophage activation syndrome (MAS), polyarteritis nodosa, immunoglobulin A (IgA) vasculitis (Henoch-Schönlein purpura [HSP]), and infections. (See
         <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">
          "Kawasaki disease: Clinical features and diagnosis", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4267015517">
         <span class="h3">
          Musculoskeletal complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common musculoskeletal complications in KD are arthralgia and arthritis, occurring in 4.6 to 17.6 percent of patients in historical cohorts and 20 percent in one retrospective case series of patients with refractory KD [
         <a href="#rid38">
          38
         </a>
         ]. Arthritis can occur during the acute (early-onset) or subacute (late-onset) phase. Patients with early- versus late-onset arthritis tend to be older (4.9 versus 2.8 years, respectively). Additionally, polyarticular involvement of the upper extremities (elbows and fingers, especially the proximal interphalangeal joints) is predominant in early-onset arthritis, whereas involvement of large joints of the lower extremities (knees, ankles, and hips) is more common with a late-onset presentation. Patients with arthritis and KD may have somewhat higher acute phase reactants than those with KD alone, but the arthritis is not associated with more severe KD or more coronary artery abnormalities (CAAs). The arthritis typically is self-limited, rarely persisting for longer than two weeks. However, most patients with persistent arthritis require treatment, usually with nonsteroidal antiinflammatory drugs (NSAIDs) and, in some cases, a short course of glucocorticoids.
        </p>
        <p>
         Uncommonly, patients with KD can present with a juvenile dermatomyositis-like picture (myositis with normal or mildly elevated muscle enzymes and proximal muscle weakness that requires treatment with glucocorticoids [
         <a href="#rid39">
          39
         </a>
         ]) or clinical features consistent with systemic juvenile idiopathic arthritis (sJIA) [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1158599777">
         <span class="h3">
          Central nervous system
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, direct vasculitic effects on the brain in KD are unusual, and autopsy studies before the introduction of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         treatment showed minimal central nervous system involvement [
         <a href="#rid26">
          26
         </a>
         ]. Irritability is a feature of the acute illness and is thought to be related to the cerebral spinal fluid pleocytosis seen in up to 40 percent of children with KD. Data regarding potential long-term behavioral problems are variable.
        </p>
        <p>
         A retrospective study of 65 patients reported an increase in long-term behavioral problems in children following KD when compared with hospital- and sibling-matched controls [
         <a href="#rid41">
          41
         </a>
         ]. In contrast, an earlier study showed no effects on the incidence of attention, behavior, or learning problems in 110 children with KD compared with a general population sample. Parents of children who had KD did express more concern about potential cardiac problems, even when their children had completely normal cardiac evaluations. Similarly, some parents reported a higher proportion of anxiety issues in their children [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3504526044">
         <span class="h3">
          Sensorineural hearing loss
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sensorineural hearing loss can occur during the acute illness, but it rarely persists. Thus, hearing tests are only performed when there is a clinical suspicion of hearing loss.
        </p>
        <p>
         A series of 40 patients seen between 2005 and 2007 was evaluated for hearing loss within the first 30 days of disease and six months later [
         <a href="#rid43">
          43
         </a>
         ]. Initial evaluation included acoustic immittance measurement and brainstem-evoked response audiometry. Those found to have hearing disability also underwent otoacoustic emissions analysis. Hearing loss was identified in 55 percent of patients within the first 30 days, and 30 percent still had hearing loss six months later. Most subjects developed conductive hearing loss; persistent sensorineural hearing loss was associated with delayed use of
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          IVIG
         </a>
         and prolonged thrombocytosis, anemia, and an elevated erythrocyte sedimentation rate (ESR). An earlier study in which inflammation due to KD was successfully controlled with IVIG demonstrated a similar early incidence of auditory abnormalities, but these resolved over several months in the vast majority of cases [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1750696856">
         <span class="h3">
          Ocular complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary ocular feature of KD is bulbar conjunctivitis. Ocular complications of KD include anterior uveitis as well as iridocyclitis, vitreous opacities, papilledema, and subconjunctival hemorrhage [
         <a href="#rid45">
          45,46
         </a>
         ]. These ocular complications are usually successfully managed with local or systemic treatment of inflammation. Vision loss or other serious complications are rare. Management of uveitis is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6417.html" rel="external">
          "Kawasaki disease: Clinical features and diagnosis", section on 'Conjunctivitis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">
          "Uveitis: Etiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">
          "Uveitis: Treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3042391884">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110198.html" rel="external">
          "Society guideline links: Kawasaki disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H114634992">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/17130.html" rel="external">
          "Patient education: Kawasaki disease (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2507809">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – The primary complications of Kawasaki disease (KD) are cardiac sequelae, although noncardiac complications also may occur  (
         <a class="graphic graphic_table graphicRef56475" href="/z/d/graphic/56475.html" rel="external">
          table 1
         </a>
         ). Most children with KD have thrombocytosis, while low platelet counts are more common in infectious conditions. When KD and thrombocytopenia do occur simultaneously, careful evaluation for dangerous complications such as KD shock syndrome (KDSS) or macrophage activation syndrome (MAS) is necessary. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Shock
         </strong>
         – KDSS, defined as sustained systolic hypotension or clinical signs of poor perfusion, is a potentially life-threatening complication. (See
         <a class="local">
          'Shock'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Macrophage activation syndrome
         </strong>
         – MAS is a rare and potentially life-threatening complication of KD that should be considered in patients with persistent fever after intravenous
         <a class="drug drug_pediatric" data-topicid="83878" href="/z/d/drug information/83878.html" rel="external">
          immune globulin
         </a>
         (IVIG) therapy. (See
         <a class="local">
          'Macrophage activation syndrome'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/87499.html" rel="external">
          "Clinical features and diagnosis of hemophagocytic lymphohistiocytosis", section on 'Rheumatologic disorders/MAS'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiac sequelae
         </strong>
         – The major complication of KD is coronary artery abnormalities (CAAs; including dilatation, aneurysm, and/or stenosis). However, other cardiac sequelae can occur, including depressed ventricular function, valvular regurgitation (primarily mitral valve involvement), and pericardial effusion. Acute myocardial infarction (AMI) is the main cause of death in KD. (See
         <a class="local">
          'Cardiac complications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5772.html" rel="external">
          "Cardiovascular sequelae of Kawasaki disease: Clinical features and evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Noncoronary vascular involvement
         </strong>
         – Virtually any vascular bed may be affected by KD, and vascular changes may occur in peripheral and visceral arteries. (See
         <a class="local">
          'Noncoronary vascular involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Peripheral arterial obstruction can lead to ischemia and gangrene. (See
         <a class="local">
          'Peripheral vascular involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urinary abnormalities and kidney disease, with the exception of sterile pyuria, are uncommonly associated with KD. (See
         <a class="local">
          'Urinary abnormalities and kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Children with KD may present with a wide variety of gastrointestinal manifestations, rarely including acute abdominal catastrophes. (See
         <a class="local">
          'Gastrointestinal abnormalities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Direct vasculitic effects on the brain in KD are unusual. (See
         <a class="local">
          'Central nervous system'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sensorineural hearing loss, usually transient and asymptomatic, may develop following KD. (See
         <a class="local">
          'Central nervous system'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004; 110:2747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanegaye JT, Wilder MS, Molkara D, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics 2009; 123:e783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yim D, Ramsay J, Kothari D, Burgner D. Coronary artery dilatation in toxic shock-like syndrome: the Kawasaki disease shock syndrome. Pediatr Cardiol 2010; 31:1232.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gatterre P, Oualha M, Dupic L, et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome. Intensive Care Med 2012; 38:872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YJ, Cheng MC, Lo MH, Chien SJ. Early Differentiation of Kawasaki Disease Shock Syndrome and Toxic Shock Syndrome in a Pediatric Intensive Care Unit. Pediatr Infect Dis J 2015; 34:1163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Curtis N, Levin M. Kawasaki disease thirty years on. Curr Opin Pediatr 1998; 10:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura Y, Yashiro M, Uehara R, et al. Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease. Pediatr Int 2004; 46:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salgado AP, Ashouri N, Berry EK, et al. High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease. J Pediatr 2017; 185:112.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newburger JW, Sanders SP, Burns JC, et al. Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. Circulation 1989; 79:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yonesaka S, Takahashi T, Matubara T, et al. Histopathological study on Kawasaki disease with special reference to the relation between the myocardial sequelae and regional wall motion abnormalities of the left ventricle. Jpn Circ J 1992; 56:352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muise A, Tallett SE, Silverman ED. Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome? Pediatrics 2003; 112:e495.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           al-Eid W, al-Jefri A, Bahabri S, al-Mayouf S. Hemophagocytosis complicating Kawasaki disease. Pediatr Hematol Oncol 2000; 17:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palazzi DL, McClain KL, Kaplan SL. Hemophagocytic syndrome after Kawasaki disease. Pediatr Infect Dis J 2003; 22:663.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohga S, Ooshima A, Fukushige J, Ueda K. Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state. Eur J Pediatr 1995; 154:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Latino GA, Manlhiot C, Yeung RS, et al. Macrophage activation syndrome in the acute phase of Kawasaki disease. J Pediatr Hematol Oncol 2010; 32:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hendricks M, Pillay S, Davidson A, et al. Kawasaki disease preceding haemophagocytic lymphohistiocytosis: challenges for developing world practitioners. Pediatr Blood Cancer 2010; 54:1023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suresh N, Sankar J. Macrophage activation syndrome: a rare complication of incomplete Kawasaki disease. Ann Trop Paediatr 2010; 30:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen Y, Shang S, Zhang C, et al. Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis. Pediatr Hematol Oncol 2010; 27:244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonini G, Pagnini I, Innocenti L, et al. Macrophage activation syndrome/Hemophagocytic Lymphohistiocytosis and Kawasaki disease. Pediatr Blood Cancer 2010; 55:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh KN, Im HJ, Chung NG, et al. Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party. Eur J Haematol 2015; 94:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Gong F, Zhu W, et al. Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin Arthritis Rheum 2015; 44:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. Blood 2011; 118:4041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davì S, Minoia F, Pistorio A, et al. Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Arthritis Rheumatol 2014; 66:2871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn Circ J 1979; 43:741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomita S, Chung K, Mas M, et al. Peripheral gangrene associated with Kawasaki disease. Clin Infect Dis 1992; 14:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Veiga PA, Pieroni D, Baier W, Feld LG. Association of Kawasaki disease and interstitial nephritis. Pediatr Nephrol 1992; 6:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferriero DM, Wolfsdorf JI. Hemolytic uremic syndrome associated with Kawasaki disease. Pediatrics 1981; 68:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salcedo JR, Greenberg L, Kapur S. Renal histology of mucocutaneous lymph node syndrome (Kawasaki disease). Clin Nephrol 1988; 29:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zulian F, Falcini F, Zancan L, et al. Acute surgical abdomen as presenting manifestation of Kawasaki disease. J Pediatr 2003; 142:731.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mele T, Evans M. Intestinal obstruction as a complication of Kawasaki disease. J Pediatr Surg 1996; 31:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Akikusa JD, Laxer RM, Friedman JN. Intestinal pseudoobstruction in Kawasaki disease. Pediatrics 2004; 113:e504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lin YL, Chang TJ, Lu KC, et al. Surgical treatment of Kawasaki disease with intestinal pseudo-obstruction. Indian J Pediatr 2011; 78:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hussain RN, Ruiz G. Kawasaki disease presenting with intussusception: a case report. Ital J Pediatr 2010; 36:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prokic D, Ristic G, Paunovic Z, Pasic S. Pancreatitis and atypical Kawasaki disease. Pediatr Rheumatol Online J 2010; 8:8.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherry R, Naon H, Cohen H, et al. Common bile duct stenosis and pancreatitis in Kawasaki disease: two cases and a review of the literature. Pediatr Infect Dis J 2010; 29:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hattori S, Nozawa T, Nishimura K, et al. Characteristics of persistent arthritis with refractory Kawasaki disease: a single-center retrospective study. Sci Rep 2023; 13:9890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anjani G, Johnson N, Navid A, et al. Kawasaki disease malingering as juvenile dermatomyositis: case-based review : Myositis in Kawasaki disease. Rheumatol Int 2022; 42:913.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dogra S, Gehlot A, Suri D, et al. Incomplete Kawasaki disease followed by systemic onset juvenile idiopathic arthritis- the diagnostic dilemma. Indian J Pediatr 2013; 80:783.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlton-Conway D, Ahluwalia R, Henry L, et al. Behaviour sequelae following acute Kawasaki disease. BMC Pediatr 2005; 5:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker AL, Gauvreau K, Newburger JW, et al. Physical and psychosocial health in children who have had Kawasaki disease. Pediatrics 2003; 111:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Magalhães CM, Magalhães Alves NR, Oliveira KM, et al. Sensorineural hearing loss: an underdiagnosed complication of Kawasaki disease. J Clin Rheumatol 2010; 16:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knott PD, Orloff LA, Harris JP, et al. Sensorineural hearing loss and Kawasaki disease: a prospective study. Am J Otolaryngol 2001; 22:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ohno S, Miyajima T, Higuchi M, et al. Ocular manifestations of Kawasaki's disease (mucocutaneous lymph node syndrome). Am J Ophthalmol 1982; 93:713.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jacob JL, Polomeno RC, Chad Z, Lapointe N. Ocular manifestations of Kawasaki disease (mucocutaneous lymph node syndrome). Can J Ophthalmol 1982; 17:199.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15688 Version 23.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15302199" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Kawasaki syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15505111" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19403470" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Recognition of a Kawasaki disease shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20706709" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Coronary artery dilatation in toxic shock-like syndrome: the Kawasaki disease shock syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22273753" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26222065" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Early Differentiation of Kawasaki Disease Shock Syndrome and Toxic Shock Syndrome in a Pediatric Intensive Care Unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9529634" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Kawasaki disease thirty years on.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19564276" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Treatment of Kawasaki disease: analysis of 27 US pediatric hospitals from 2001 to 2006.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15043662" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Use of laboratory data to identify risk factors of giant coronary aneurysms due to Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28408126" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : High Risk of Coronary Artery Aneurysms in Infants Younger than 6 Months of Age with Kawasaki Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2720925" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1578606" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Histopathological study on Kawasaki disease with special reference to the relation between the myocardial sequelae and regional wall motion abnormalities of the left ventricle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14654653" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Are children with Kawasaki disease and prolonged fever at risk for macrophage activation syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845231" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hemophagocytosis complicating Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12886898" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Hemophagocytic syndrome after Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7556319" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Histiocytic haemophagocytosis in a patient with Kawasaki disease: changes in the hypercytokinaemic state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20485197" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Macrophage activation syndrome in the acute phase of Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20135702" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Kawasaki disease preceding haemophagocytic lymphohistiocytosis: challenges for developing world practitioners.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20196936" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Macrophage activation syndrome: a rare complication of incomplete Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20367269" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Hemophagocytic lymphohistiocytosis at initiation of kawasaki disease and their differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20658642" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Macrophage activation syndrome/Hemophagocytic Lymphohistiocytosis and Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24935083" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Clinical features, genetics, and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in Korea: report of a nationwide survey from Korea Histiocytosis Working Party.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25200945" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Macrophage activation syndrome in Kawasaki disease: more common than we thought?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21828139" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : How I treat hemophagocytic lymphohistiocytosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25044674" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/41114" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1571415" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Peripheral gangrene associated with Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1457322" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Association of Kawasaki disease and interstitial nephritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7279468" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Hemolytic uremic syndrome associated with Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3289806" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Renal histology of mucocutaneous lymph node syndrome (Kawasaki disease).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12838207" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute surgical abdomen as presenting manifestation of Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8811576" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Intestinal obstruction as a complication of Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15121996" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Intestinal pseudoobstruction in Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20949336" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Surgical treatment of Kawasaki disease with intestinal pseudo-obstruction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20180974" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Kawasaki disease presenting with intussusception: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20181201" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Pancreatitis and atypical Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20386488" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Common bile duct stenosis and pancreatitis in Kawasaki disease: two cases and a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37336934" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Characteristics of persistent arthritis with refractory Kawasaki disease: a single-center retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33682025" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Kawasaki disease malingering as juvenile dermatomyositis: case-based review : Myositis in Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23054859" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Incomplete Kawasaki disease followed by systemic onset juvenile idiopathic arthritis- the diagnostic dilemma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15916701" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Behaviour sequelae following acute Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12612239" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Physical and psychosocial health in children who have had Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20859226" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Sensorineural hearing loss: an underdiagnosed complication of Kawasaki disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11562886" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Sensorineural hearing loss and Kawasaki disease: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7201245" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Ocular manifestations of Kawasaki's disease (mucocutaneous lymph node syndrome).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7172107" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Ocular manifestations of Kawasaki disease (mucocutaneous lymph node syndrome).
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
